Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovative pharmaceutical company in China, and Biotheus Inc. (Biotheus), a clinical-stage biotech company specializing in biologics for oncology and inflammatory diseases, have jointly announced an expansion of their strategic partnership. This move comes as a progression of their existing collaboration initiated in 2022.
Biotheus will grant Hansoh Pharma a license to utilize their proprietary anti-EGFR/cMet bispecific antibody HS-20117/PM1080 for the independent development of antibody-drug conjugate products (ADC Products).
Under the agreement, Hansoh Pharma will gain exclusive worldwide rights from Biotheus to employ HS-20117/PM1080 in the development, production, and commercialization of ADC Products, with sublicensing rights. Biotheus stands to receive up to 5 billion RMB in upfront and success-based milestones for ADC Products, along with tiered royalties based on global net sales from Hansoh Pharma.
HS-20117/PM1080, a 1+1 heterodimeric structure of EGFR/cMet bispecific antibody, is currently undergoing phase I clinical trials. It targets tumor antigens EGFR and cMet, thereby inhibiting tumor growth and survival.
Ms. Eliza Sun, Executive Director of the Board at Hansoh, expressed excitement about expanding the partnership with Biotheus. She highlighted the collaboration’s potential to enhance clinical benefits for patients with NSCLC or other solid tumors, leveraging Hansoh’s ADC Platform technology and Biotheus’ bispecific antibody.
Mr. Xiaolin Liu, Co-founder, Chairman, and CEO of Biotheus, emphasized the significance of this collaboration, citing the potential advantages of bispecific ADCs in tumor enrichment, efficacy, and safety. He praised Hansoh’s ADC platform and anticipated a synergy between their expertise and Biotheus’ antibody capabilities to develop a novel EGFR/MET bispecific ADC for cancer patients worldwide.
Hansoh Pharma is a leading pharmaceutical company in Greater China, driven by innovation. It focuses on treating major diseases such as oncology, anti-infections, CNS diseases, metabolic diseases, and autoimmune diseases, with a commitment to improving human health through continuous innovation. Hansoh Pharma has consistently ranked among the top 100 global pharmaceutical companies and the top 3 industrial enterprises in China in terms of pharmaceutical R&D pipeline. It is a national key high-tech enterprise and a national technology innovation demonstration enterprise. Hansoh Pharma was listed on the Stock Exchange of Hong Kong in June 2019 (stock
Biotheus is a clinical-stage biotech company dedicated to discovering, developing, and delivering novel antibodies to address unmet medical needs in oncology and inflammatory diseases worldwide. With innovative antibody discovery platforms and an experienced R&D team, Biotheus has built a differentiated product pipeline with programs at various stages.
